Skip to content
MARKETS / NASDAQ / QSI
NASDAQ · MEASURING & CONTROLLING DEVICES, NEC · SMALL CAP

Quantum-Si Inc. QSI

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.4M
▼ 20.3% YoY
$-101.3M
$-97.2M
In brief

What this company does

We are a life sciences company focused on proteomics research, with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. We have developed a proprietary, universal, single-molecule detection platform that we are applying to proteomics to enable next-gen protein sequencing (“NGPS”) to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), which can also be used for the study of nucleic acids. Our current platform includes our Platinum® NGPS line of instruments, Platinum Analysis Software and consumable kits for use with our Platinum line of instruments. In January 2025, we announced the launch of our Platinum Pro benchtop sequencer. Our team has decades of cumulative experience in developing, commercializing and scaling tools in the life sciences industry.

Written from the business description in Quantum-Si Incorporated's annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.

Growth
USD 2.4M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.4 · Net income -101.3
-50M-100M2019202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−4160 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -4766.0% · Net -4160.1%
-5000%-10000%2019202020212022202320242025
ROE
FY2025 · ROE -46.5%
-20%-40%2019202020212022202320242025

Each USD of equity lost 47 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -97.2
-40M-80M2019202020212022202320242025

Total assetsUSD 245.6M
EquityUSD 220.2M
CashUSD 21.6M
Current ratio7.64×

Equity funds 90% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.0··
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−0.51−0.71−0.68−0.95−1.19−6.84−6.95
Dividend / sh $·······
Payout %·······
ROE %−46.5−41.5−30.4−31.7−59.9··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 31 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 64 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMeasuring & Controlling Devices, NEC
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image